Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRUIN-CLL-313: Pirtobrutinib vs bendamustine + rituximab in untreated CLL/SLL
2021-001234-20Phase 3Active
- Sponsor
- Loxo Oncology
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pirtobrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Loxo Oncology. Primary endpoint: Progression-free survival (PFS). Started Jul 2021; status: active.
02
Drugs
pirtobrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2021-001234-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001234-20.